BlossomHill Therapeutics, Inc. BLSM
Set alert
12.42 USD -1.33 -9.67%
At close · Nov 2
12.42 0.00 0.00%
After hours · Nov 2, 4:00 PM ET
12.28 Day range 14.23
12.28 52-week range 27.99
- YTD
- -22.38%
- 1 year
- -22.38%
- Open
- 13.80
- Prev close
- 13.75
- Mkt cap
- 394.77M
- Vol
- 140.76K
- Avg vol
- 226.76K
- EPS
- -4.70
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 12.28
- High
- 14.23
30m chart
Built from the cached five-day intraday bars.
Signals (12)
| Name | Time | Ago |
|---|---|---|
| RSI: Oversold | Nov 2, 4:00 PM | 7 hours ago |
| SMA: Bearish | Nov 2, 3:20 PM | 8 hours ago |
| SMA: Bullish | Nov 2, 2:50 PM | 9 hours ago |
| MACD: Buy Signal | Nov 2, 2:50 PM | 9 hours ago |
| RSI: Oversold | Nov 2, 1:45 PM | 10 hours ago |
| RSI: Oversold | Oct 30, 3:20 PM | 3 days ago |
| RSI: Oversold | Oct 30, 10:00 AM | 3 days ago |
| RSI: Oversold | Oct 29, 2:35 PM | 4 days ago |
| SMA: Bearish | Oct 29, 11:15 AM | 4 days ago |
| SMA: Bullish | Oct 28, 12:35 PM | 5 days ago |
| SMA: Bearish | Oct 28, 10:50 AM | 5 days ago |
| SMA: Bullish | Oct 28, 10:25 AM | 5 days ago |
Financials — quick view
BLSM Revenue — quarterly 0
BLSM Net income — quarterly -23.76M
BLSM EPS — quarterly -8.75
News
- BlossomHill Therapeutics: A Deliberate Beachhead Trading Back At Its IPO Price
- BlossomHill Therapeutics Collaborates With Foundation Medicine To Develop Companion Diagnostic Assay For EGFR C797S Resistance Mutation
- BlossomHill Therapeutics Announces Collaboration with Foundation Medicine to Develop First Companion Diagnostic for BH-30643 in EGFR C797S Mutated Non-Small Cell Lung Cancer
- BlossomHill Therapeutics (NASDAQ:BLSM) Shares Down 4.9% – Time to Sell?
- BlossomHill Therapeutics (NASDAQ:BLSM) Shares Gap Up – Here’s Why
- BlossomHill Therapeutics Presents Preclinical Data On BH-501284 At AACR Conference On Pancreatic Cancer; Targets IND Filing In Q1 2027
- BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer
- Leerink Partners Maintains Outperform on BlossomHill Therapeutics, Raises Price Target to $40
- Guggenheim Maintains Buy on BlossomHill Therapeutics, Raises Price Target to $40
- Earnings Scheduled For September 18, 2026
Your note
Sign in to keep a note on BLSM — it syncs with the Stock Master app.